The detection of one such variant (i.e., AR splice variant Arv7) in circulating tumor cells or in peripheral whole blood, without the need for CTC capture, can predict poor response to abiraterone and enzalutamide, i.e., second-generation AR antagonists [50,51]. Here, AR is linked to neoplasm.